Literature DB >> 30705842

Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer.

Chen Zhao1, Nobuyuki Takahashi1, Arun Rajan1.   

Abstract

Entities:  

Year:  2018        PMID： 30705842      PMCID： PMC6328694          DOI： 10.21037/tlcr.2018.12.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

1.  A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Authors:  Arun Rajan; Corey A Carter; Ronan J Kelly; Martin Gutierrez; Shivaani Kummar; Eva Szabo; Mary Ann Yancey; Jiuping Ji; Baskar Mannargudi; Sukyung Woo; Shawn Spencer; William Douglas Figg; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

2.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Authors:  Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

3.  Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Authors:  M Catherine Pietanza; Kyuichi Kadota; Kety Huberman; Camelia S Sima; John J Fiore; Dyana K Sumner; William D Travis; Adriana Heguy; Michelle S Ginsberg; Andrei I Holodny; Timothy A Chan; Naiyer A Rizvi; Christopher G Azzoli; Gregory J Riely; Mark G Kris; Lee M Krug
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

4.  Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Authors:  Malcolm A Smith; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard B Lock; Stephen T Keir; John M Maris; Catherine A Billups; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2014-12-10       Impact factor: 12.531

Review 5.  Chemopotentiation by PARP inhibitors in cancer therapy.

Authors:  Lucio Tentori; Grazia Graziani
Journal:  Pharmacol Res       Date:  2005-07       Impact factor: 7.658

6.  ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.

Authors:  Joann P Palma; Yi-Chun Wang; Luis E Rodriguez; Debra Montgomery; Paul A Ellis; Gail Bukofzer; Amanda Niquette; Xuesong Liu; Yan Shi; Loren Lasko; Gui-Dong Zhu; Thomas D Penning; Vincent L Giranda; Saul H Rosenberg; David J Frost; Cherrie K Donawho
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 7.  Causes and consequences of replication stress.

Authors:  Michelle K Zeman; Karlene A Cimprich
Journal:  Nat Cell Biol       Date:  2014-01       Impact factor: 28.824

8.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Authors:  Lauren Averett Byers; Jing Wang; Monique B Nilsson; Junya Fujimoto; Pierre Saintigny; John Yordy; Uma Giri; Michael Peyton; You Hong Fan; Lixia Diao; Fatemeh Masrorpour; Li Shen; Wenbin Liu; Boris Duchemann; Praveen Tumula; Vikas Bhardwaj; James Welsh; Stephanie Weber; Bonnie S Glisson; Neda Kalhor; Ignacio I Wistuba; Luc Girard; Scott M Lippman; Gordon B Mills; Kevin R Coombes; John N Weinstein; John D Minna; John V Heymach
Journal:  Cancer Discov       Date:  2012-09-06       Impact factor: 39.397

9.  Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.

Authors:  Gabriele Zoppoli; Marie Regairaz; Elisabetta Leo; William C Reinhold; Sudhir Varma; Alberto Ballestrero; James H Doroshow; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

10.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.